PMID- 28079912
OWN - NLM
STAT- MEDLINE
DCOM- 20170502
LR  - 20170502
IS  - 1938-2359 (Electronic)
IS  - 0090-4481 (Linking)
VI  - 46
IP  - 1
DP  - 2017 Jan 1
TI  - Intravenous Immunoglobulin in the Treatment of Primary Immunodeficiency Diseases.
PG  - e8-e12
LID - 10.3928/19382359-20161213-03 [doi]
AB  - Intravenous immunoglobulin (IVIG) has been used as antibody replacement therapy 
      in primary immunodeficiency diseases (PIDDs) for more than 50 years. Its role as 
      a therapeutic agent has expanded over the past couple of decades as its 
      anti-inflammatory and immune-modulatory mechanisms of action have been 
      elucidated. It is now used "off-label" to treat other autoimmune diseases. This 
      article focuses on the role of IVIG in the treatment of PIDDs characterized by 
      absent or deficient antibody production. Replacement doses are given on a monthly 
      basis in these conditions as a prophylactic measure to prevent acute and serious 
      bacterial infections. [Pediatr Ann. 2017;46(1):e8-e12.].
CI  - Copyright 2017, SLACK Incorporated.
FAU - De Ranieri, Deirdre
AU  - De Ranieri D
FAU - Fenny, Nana Sarkoah
AU  - Fenny NS
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Pediatr Ann
JT  - Pediatric annals
JID - 0356657
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunologic Deficiency Syndromes/*therapy
EDAT- 2017/01/13 06:00
MHDA- 2017/05/04 06:00
CRDT- 2017/01/13 06:00
PHST- 2017/01/13 06:00 [entrez]
PHST- 2017/01/13 06:00 [pubmed]
PHST- 2017/05/04 06:00 [medline]
AID - 10.3928/19382359-20161213-03 [doi]
PST - ppublish
SO  - Pediatr Ann. 2017 Jan 1;46(1):e8-e12. doi: 10.3928/19382359-20161213-03.